Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2019

Open Access 01-12-2019 | Breast Cancer | Research

HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1

Authors: Rossella Zanin, Silvia Pegoraro, Gloria Ros, Yari Ciani, Silvano Piazza, Fleur Bossi, Roberta Bulla, Cristina Zennaro, Federica Tonon, Dejan Lazarevic, Elia Stupka, Riccardo Sgarra, Guidalberto Manfioletti

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2019

Login to get access

Abstract

Background

Breast cancer is the most common malignancy in women worldwide. Among the breast cancer subtypes, triple-negative breast cancer (TNBC) is the most aggressive and the most difficult to treat. One of the master regulators in TNBC progression is the architectural transcription factor HMGA1. This study aimed to further explore the HMGA1 molecular network to identify molecular mechanisms involved in TNBC progression.

Methods

RNA from the MDA-MB-231 cell line, silenced for HMGA1 expression, was sequenced and, with a bioinformatic analysis, molecular partners HMGA1 could cooperate with in regulating common downstream gene networks were identified. Among the putative partners, the FOXM1 transcription factor was selected. The relationship occurring between HMGA1 and FOXM1 was explored by qRT-PCR, co-immunoprecipitation and protein stability assays. Subsequently, the transcriptional activity of HMGA1 and FOXM1 was analysed by luciferase assay on the VEGFA promoter. The impact on angiogenesis was assessed in vitro, evaluating the tube formation ability of endothelial cells exposed to the conditioned medium of MDA-MB-231 cells silenced for HMGA1 and FOXM1 and in vivo injecting MDA-MB-231 cells, silenced for the two factors, in zebrafish larvae.

Results

Here, we discover FOXM1 as a novel molecular partner of HMGA1 in regulating a gene network implicated in several breast cancer hallmarks. HMGA1 forms a complex with FOXM1 and stabilizes it in the nucleus, increasing its transcriptional activity on common target genes, among them, VEGFA, the main inducer of angiogenesis. Furthermore, we demonstrate that HMGA1 and FOXM1 synergistically drive breast cancer cells to promote tumor angiogenesis both in vitro in endothelial cells and in vivo in a zebrafish xenograft model. Moreover, using a dataset of breast cancer patients we show that the co-expression of HMGA1, FOXM1 and VEGFA is a negative prognostic factor of distant metastasis-free survival and relapse-free survival.

Conclusions

This study reveals FOXM1 as a crucial interactor of HMGA1 and proves that their cooperative action supports breast cancer aggressiveness, by promoting tumor angiogenesis. Therefore, the possibility to target HMGA1/FOXM1 in combination should represent an attractive therapeutic option to counteract breast cancer angiogenesis.
Appendix
Available only for authorised users
Literature
1.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.PubMedCrossRef
2.
Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7(12):683–92.PubMedCrossRef
3.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.PubMedCrossRef
4.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(15 Pt 1):4429–34.CrossRef
5.
Mohammed RAA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, et al. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol Off J U S Can Acad Pathol Inc. 2011;24(6):774–85.
6.
Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–22.PubMedCrossRef
7.
Sgarra R, Pegoraro S, Ros G, Penzo C, Chiefari E, Foti D, et al. High mobility group a (HMGA) proteins: molecular instigators of breast cancer onset and progression. Biochim Biophys Acta Rev Cancer. 2018;1869(2):216–29.PubMedCrossRef
8.
Munshi N, Agalioti T, Lomvardas S, Merika M, Chen G, Thanos D. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science. 2001;293(5532):1133–6.PubMedCrossRef
9.
Sgarra R, Zammitti S, Lo Sardo A, Maurizio E, Arnoldo L, Pegoraro S, et al. HMGA molecular network: from transcriptional regulation to chromatin remodelling. Biochim Biophys Acta. 2010;1799(1–2):37–47.PubMedCrossRef
10.
Sumter TF, Xian L, Huso T, Koo M, Chang Y-T, Almasri TN, et al. The high mobility group A1 (HMGA1) transcriptome in Cancer and development. Curr Mol Med. 2016;16(4):353–93.PubMedPubMedCentralCrossRef
11.
Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004;574:1–3):1–8.PubMedCrossRef
12.
13.
Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget. 2013;4(8):1293–308.PubMedPubMedCentralCrossRef
14.
Baldassarre G, Belletti B, Battista S, Nicoloso MS, Pentimalli F, Fedele M, et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene. 2005;24(45):6809–19.PubMedCrossRef
15.
Huang R, Huang D, Dai W, Yang F. Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer. Mol Cell Biochem. 2015;404(1–2):251–7.PubMedCrossRef
16.
Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene. 2001;277(1–2):63–81.PubMedCrossRef
17.
Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC, et al. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One. 2013;8(5):e63419.PubMedPubMedCentralCrossRef
18.
Pegoraro S, Ros G, Ciani Y, Sgarra R, Piazza S, Manfioletti G. A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget. 2015;6(22):19087–101.PubMedPubMedCentralCrossRef
19.
Maurizio E, Wiśniewski JR, Ciani Y, Amato A, Arnoldo L, Penzo C, et al. Translating proteomic into functional data: an high mobility group A1 (HMGA1) proteomic signature has prognostic value in breast Cancer. Mol Cell Proteomics MCP. 2016;15(1):109–23.PubMedCrossRef
20.
Resmini G, Rizzo S, Franchin C, Zanin R, Penzo C, Pegoraro S, et al. HMGA1 regulates the plasminogen activation system in the secretome of breast cancer cells. Sci Rep. 2017;7(1):11768.PubMedPubMedCentralCrossRef
21.
Koo C-Y, Muir KW, Lam EW-F. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819(1):28–37.PubMedCrossRef
22.
Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–419.PubMedCrossRef
23.
24.
Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009;28(19):2908–18.PubMedPubMedCentralCrossRef
25.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma Oxf Engl. 2013;29(1):15–21.CrossRef
26.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinforma Oxf Engl. 2010;26(1):139–40.CrossRef
27.
de Hoon MJL, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinforma Oxf Engl. 2004;20(9):1453–4.CrossRef
28.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545–50.CrossRefPubMedPubMedCentral
29.
Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.PubMedCrossRef
30.
Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinforma Oxf Engl. 2014;30(4):523–30.CrossRef
31.
Dean CB, Nielsen JD. Generalized linear mixed models: a review and some extensions. Lifetime Data Anal. 2007;13(4):497–512.PubMedCrossRef
32.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.CrossRef
33.
Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.CrossRef
34.
Bossi F, Tripodo C, Rizzi L, Bulla R, Agostinis C, Guarnotta C, et al. C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci. 2014;111(11):4209-14.CrossRef
35.
Tonon F, Zennaro C, Dapas B, Carraro M, Mariotti M, Grassi G. Rapid and cost-effective xenograft hepatocellular carcinoma model in zebrafish for drug testing. Int J Pharm. 2016;515(1–2):583–91.PubMedCrossRef
36.
Delov V, Muth-Köhne E, Schäfers C, Fenske M. Transgenic fluorescent zebrafish Tg (fli1:EGFP)y1 for the identification of vasotoxicity within the zFET. Aquat Toxicol Amst Neth. 2014;150:189–200.CrossRef
37.
Jung D-W, Oh E-S, Park S-H, Chang Y-T, Kim C-H, Choi S-Y, et al. A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening. Mol BioSyst. 2012;8(7):1930–9.PubMedCrossRef
38.
Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160(3):439–46.PubMedCrossRef
39.
Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res. 2008;68(24):10121–7.PubMedPubMedCentralCrossRef
40.
Ueda Y, Watanabe S, Tei S, Saitoh N, Kuratsu J-I, Nakao M. High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest. Cancer Sci. 2007;98(12):1893–901.PubMedCrossRef
41.
42.
43.
44.
Pagès G, Pouysségur J. Transcriptional regulation of the vascular endothelial growth factor gene--a concert of activating factors. Cardiovasc Res. 2005;65(3):564–73.PubMedCrossRef
45.
Chiefari E, Ventura V, Capula C, Randazzo G, Scorcia V, Fedele M, et al. A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression. Sci Rep. 2016;6:39429.PubMedPubMedCentralCrossRef
46.
Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho K-K, Zwolinska AK, et al. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 2012;31(14):1845–58.PubMedCrossRef
47.
Wood LW, Cox NI, Phelps CA, Lai S-C, Poddar A, Talbot C, et al. Thyroid transcription factor 1 reprograms Angiogenic activities of Secretome. Sci Rep. 2016;6:19857.PubMedPubMedCentralCrossRef
48.
49.
Littler DR, Alvarez-Fernández M, Stein A, Hibbert RG, Heidebrecht T, Aloy P, et al. Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence. Nucleic Acids Res. 2010;38(13):4527–38.PubMedPubMedCentralCrossRef
50.
Pore N, Liu S, Shu H-K, Li B, Haas-Kogan D, Stokoe D, et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell. 2004;15(11):4841–53.PubMedPubMedCentralCrossRef
51.
Foti D, Iuliano R, Chiefari E, Brunetti A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol. 2003;23(8):2720–32.PubMedPubMedCentralCrossRef
52.
Weinstein B. Vascular cell biology in vivo: a new piscine paradigm? Trends Cell Biol. 2002;12(9):439–45.PubMedCrossRef
53.
Tobia C, De Sena G, Presta M. Zebrafish embryo, a tool to study tumor angiogenesis. Int J Dev Biol. 2011;55(4–5):505–9.PubMedCrossRef
54.
55.
Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol. 2001;21(2):575–94.PubMedPubMedCentralCrossRef
56.
57.
DiMeo TA, Anderson K, Phadke P, Fan C, Feng C, Perou CM, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009;69(13):5364–73.PubMedPubMedCentralCrossRef
58.
Saba R, Alsayed A, Zacny JP, Dudek AZ. The role of Forkhead box protein M1 in breast Cancer progression and resistance to therapy. Int J Breast Cancer. 2016;2016:9768183.PubMedPubMedCentralCrossRef
59.
60.
Bhat UG, Jagadeeswaran R, Halasi M, Gartel AL. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J Biol Chem. 2011;286(48):41425–33.PubMedPubMedCentralCrossRef
61.
Yang L, He K, Yan S, Yang Y, Gao X, Zhang M, et al. Metadherin/astrocyte elevated gene-1 positively regulates the stability and function of forkhead box M1 during tumorigenesis. Neuro-Oncol. 2017;19(3):352–63.PubMed
62.
Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008;68(21):8733–42.PubMedPubMedCentralCrossRef
63.
Messineo S, Laria AE, Arcidiacono B, Chiefari E, Luque Huertas RM, Foti DP, et al. Cooperation between HMGA1 and HIF-1 contributes to hypoxia-induced VEGF and Visfatin gene expression in 3T3-L1 adipocytes. Front Endocrinol. 2016;7:73.CrossRef
64.
Camós S, Gubern C, Sobrado M, Rodríguez R, Romera VG, Moro MA, et al. The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins. Neuroscience. 2014;269:112–30.PubMedCrossRef
65.
Qi C, Li B, Yang Y, Yang Y, Li J, Zhou Q, et al. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis. Sci Rep. 2016;6:27819.PubMedPubMedCentralCrossRef
66.
Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem. 2011;3(9):725–31.PubMedCrossRef
67.
68.
Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinković D, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014;5:5165.PubMedCrossRef
69.
D’Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, et al. The impairment of the high mobility group a (HMGA) protein function contributes to the anticancer activity of trabectedin. Eur J Cancer. 2013;49(5):1142–51.PubMedCrossRef
70.
Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, et al. HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene. 2018;37(45):5926–38.PubMedPubMedCentralCrossRef
Metadata
Title
HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1
Authors
Rossella Zanin
Silvia Pegoraro
Gloria Ros
Yari Ciani
Silvano Piazza
Fleur Bossi
Roberta Bulla
Cristina Zennaro
Federica Tonon
Dejan Lazarevic
Elia Stupka
Riccardo Sgarra
Guidalberto Manfioletti
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2019
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-019-1307-8

Other articles of this Issue 1/2019

Journal of Experimental & Clinical Cancer Research 1/2019 Go to the issue

Correction

Correction to: Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells

Research

Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion

Research

P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs

Research

Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation

Review

Effects of hyperglycemia on the progression of tumor diseases

Research

NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits